16 April 2015 - Deborah Wilkes
Archived
Johnson & Johnson's OTC sales in the US increased by 10.7% to US$405 million in the first quarter of 2015, as the company's McNeil Consumer Healthcare subsidiary waits for an end to the consent decree filed by the US Department of Justice and the US Food and Drug Administration (FDA) in 2011 following manufacturing problems in the US.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.